Effect of Organophoshate Exposure on Cholesteryl Ester Hydrolase

有机磷酸盐暴露对胆固醇酯水解酶的影响

基本信息

  • 批准号:
    7811262
  • 负责人:
  • 金额:
    $ 6.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-25 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The rate-limiting step in reverse cholesterol transport from macrophages is the hydrolysis of cholesteryl esters to free cholesterol, which is subsequently transported out of the cell to cholesterol acceptors. In human macrophages, the enzyme responsible for cholesteryl ester hydrolysis is carboxylesterase 1 (CES1). The overall hypothesis of parent grant R15 ES015348 was that exposure to bioactive metabolites of organophosphate (OP) insecticides will inhibit the ability of CES1 to hydrolyze cholesteryl esters, thus slowing the reverse cholesterol transport process and increasing the risk of atherosclerosis. Our published data, obtained during the current funding cycle, shows that CES1 can be inhibited by treatment with paraoxon, the active metabolite of the OP insecticide parathion, and that this inhibition can cause augmented accumulation of cholesteryl esters in human THP-1 macrophages (Crow et al., 2008). Moreover, our recent preliminary data show that recombinant CES1 and CES2 can hydrolyze the endocannabinoid compound 2-arachidonoylglycerol (2-AG) and its COX-2 derived prostaglandin-like metabolites (termed prostaglandin glyceryl esters or PG-Gs). Pretreatment of human THP-1 monocytes and macrophages with paraoxon can block the subsequent degradation of exogenously added 2-AG and PG-Gs. These are novel findings that suggest that exposure of CES1- and/or CES2-expressing cells to bioactive OP metabolites (e.g., paraoxon) will perturb the endocannabinoid tone in tissues composed of these cells. It has become increasingly clear that endogenous cannabinoids, which bind to the same class of receptors as the psychoactive component of marijuana (?9-THC), have important functions in health and disease. Therefore, we hypothesize that the endocannabinoid tone of vessel wall macrophages will be significantly perturbed by chronic exposure to bioactive OP metabolites and an activated endocannabinoid system can modulate cholesterol metabolism in macrophages. To explore this possibility, we propose to extend the scope of R15 ES015348 by studying the endocannabinoid system in a model cell culture system (macrophage foam cells) that we already use in the parent grant. To test our hypothesis we propose two aims: (1) Determine if combined treatment of cultured human THP-1 macrophages with oxidized (ox)LDL and bioactive metabolites of OP pesticides modulate components of the endocannabinoid system, including cannabinoid (CB) receptor levels, endocannabinoid biosynthetic enzymes, endocannabinoid catabolic enzymes (MAGL and CES1), and the levels of endocannabinoids themselves (2-AG and AEA). (2) Determine if endocannabinoids (2-AG and AEA) modulate cholesterol metabolism and efflux from human macrophages via a CB1- or CB2-mediated mechanism. PUBLIC HEALTH RELEVANCE: Atherosclerosis is the number one killer in the United States. The underlying pathophysiology of atherosclerosis is complex and multifactorial. One critical factor in the development/progression of atherosclerosis is environmental factors, such as toxicants, that may accelerate disease. Our research seeks to examine whether organophosphate (OP) pesticides are etiologically associated with atherosclerosis. Our research indicates that there are enzymes that regulate cholesterol metabolism, which can be inhibited by bioactive metabolites of OP pesticides. This competitive supplement will allow us to study these mechanisms in greater detail.
描述(由申请人提供):从巨噬细胞中反向胆固醇转运的速率限制步骤是将胆固醇酯的水解为释放胆固醇,随后将其从细胞中输送到胆固醇受体。在人类巨噬细胞中,负责胆固醇酯水解的酶是羧酸酯酶1(CES1)。父授予R15 ES015348的总体假设是,暴露于有机磷酸盐(OP)杀虫剂的生物活性代谢物将抑制CES1水解胆固醇酯的能力,从而减慢反向胆固醇的转运过程并增加动脉粥样硬化的风险。我们在当前资助周期中获得的已发表数据表明,CES1可以通过用二氧氧克子(Paraoxon)(OP杀虫剂parathion的活性代谢产物)治疗抑制CES1,并且这种抑制作用会导致人类THP-1巨噬细胞中胆固醇酯的积累增加(Crow等,2008)。此外,我们最近的初步数据表明,重组CES1和CES2可以水解内源性大麻素化合物2-芳基烯丙基甘油(2-AG)及其COX-2衍生的前列腺素样代谢物(称为Prostaglandin Glycerlin Glycernin Glyceryl酯或PG-GS)。用二氧谁对人Thp-1单核细胞和巨噬细胞的预处理可以阻止外源添加的2AG和PG-GS的随后降解。这些新发现表明,表达CES1-和/或CES2细胞对生物活性OP代谢产物(例如副代谢物)的暴露会扰动由这些细胞组成的组织中的内源性大麻素张力。越来越清楚的是,内源性大麻素与大麻的精神活性成分(?9-THC)结合,在健康和疾病中具有重要功能。因此,我们假设血管壁巨噬细胞的内源性大麻素张力会因长期暴露于生物活性OP代谢物而显着干扰,而活化的内源性大麻素系统可以调节巨噬细胞中的胆固醇代谢。为了探索这种可能性,我们建议通过研究我们已经在父母赠款中使用的模型细胞培养系统(巨噬细胞泡沫细胞)中的内源性大麻素系统来扩展R15 ES015348的范围。为了检验我们的假设,我们提出了两个目的:(1)确定培养的人Thp-1巨噬细胞与OP农药的氧化(OX)LDL和生物活性代谢物的结合处理是否会调节内源性网诺生物系统的组成部分,包括大麻素(CB)受体水平,内切型生物酶(cabanbinabiin andercantiennthethionthethionththebien),伴奏酶辅助酶(CAB),酶辅助酶,并伴随CES1),以及内源性大麻素本身(2-AG和AEA)。 (2)确定内源性大麻素(2-AG和AEA)是否通过CB1或CB2介导的机制调节了人类巨噬细胞的胆固醇代谢和外排。 公共卫生相关性:动脉粥样硬化是美国排名第一的杀手。动脉粥样硬化的基本病理生理学是复杂而多因素的。动脉粥样硬化的发展/进展的一个关键因素是环境因素,例如有毒物质,可能会加速疾病。我们的研究试图检查有机磷酸盐(OP)农药是否与动脉粥样硬化有关。我们的研究表明,有一些调节胆固醇代谢的酶可以被OP农药的生物活性代谢产物抑制。这种竞争性补充剂将使我们能够更详细地研究这些机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW K ROSS其他文献

MATTHEW K ROSS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW K ROSS', 18)}}的其他基金

Crosstalk between CES1 and PPAR gamma and LXR alpha in macrophages
巨噬细胞中 CES1 与 PPAR γ 和 LXR α 之间的串扰
  • 批准号:
    10359914
  • 财政年份:
    2022
  • 资助金额:
    $ 6.72万
  • 项目类别:
Effect of Organophoshate Exposure on Cholesteryl Ester Hydrolase
有机磷酸盐暴露对胆固醇酯水解酶的影响
  • 批准号:
    7908563
  • 财政年份:
    2009
  • 资助金额:
    $ 6.72万
  • 项目类别:
Effect of Organophoshate Exposure on Cholesteryl Ester Hydrolase
有机磷酸盐暴露对胆固醇酯水解酶的影响
  • 批准号:
    7304498
  • 财政年份:
    2007
  • 资助金额:
    $ 6.72万
  • 项目类别:
Lipid glyceryl ester homeostasis in macrophages and perturbation by environmental
巨噬细胞中的脂质甘油酯稳态和环境扰动
  • 批准号:
    8232778
  • 财政年份:
    2007
  • 资助金额:
    $ 6.72万
  • 项目类别:
KINETIC ANALYSES OF SITE-SPECIFIC MUTANTS OF CARBOXYLESTERASES
羧基酯酶位点特异性突变体的动力学分析
  • 批准号:
    7381820
  • 财政年份:
    2006
  • 资助金额:
    $ 6.72万
  • 项目类别:
BIOTRANSFORMATION AND PHARMACOKINETICS OF PYRETHROID INSECTICIDES
拟除虫菊酯类杀虫剂的生物转化和药代动力学
  • 批准号:
    7381816
  • 财政年份:
    2006
  • 资助金额:
    $ 6.72万
  • 项目类别:
BIOTRANSFORMATION AND PHARMACOKINETICS OF PYRETHROID INSECTICIDES
拟除虫菊酯类杀虫剂的生物转化和药代动力学
  • 批准号:
    7171040
  • 财政年份:
    2005
  • 资助金额:
    $ 6.72万
  • 项目类别:
BIOTRANSFORMATION OF PYRETHROID INSECTICIDES
拟除虫菊酯杀虫剂的生物转化
  • 批准号:
    6981726
  • 财政年份:
    2004
  • 资助金额:
    $ 6.72万
  • 项目类别:
Trihalomethane Pharmacokinetics and Pharmacodynamics
三卤甲烷药代动力学和药效学
  • 批准号:
    6525336
  • 财政年份:
    2002
  • 资助金额:
    $ 6.72万
  • 项目类别:
Trihalomethane Pharmacokinetics and Pharmacodynamics
三卤甲烷药代动力学和药效学
  • 批准号:
    6747546
  • 财政年份:
    2002
  • 资助金额:
    $ 6.72万
  • 项目类别:

相似国自然基金

面向掌纹识别的安全与隐私保护理论和方法研究
  • 批准号:
    62376211
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
微观市场均衡视角下中国长期护理保险试点的福利分析与政策评估
  • 批准号:
    72304093
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
面向康复护理机器人的人机信任度评估方法与任务影响机制研究
  • 批准号:
    62306195
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
基于生命质量的癌症患者心理行为与护理干预
  • 批准号:
    72381240026
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    国际(地区)合作与交流项目
天然水体中药品和个人护理品间接光降解产物预测模型的构建和应用
  • 批准号:
    42307496
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh
硝唑尼特治疗孟加拉国营养不良儿童隐孢子虫感染的随机对照试验
  • 批准号:
    10551559
  • 财政年份:
    2023
  • 资助金额:
    $ 6.72万
  • 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
  • 批准号:
    10456380
  • 财政年份:
    2023
  • 资助金额:
    $ 6.72万
  • 项目类别:
Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors
工程组织阵列可简化去免疫 DMD 基因治疗载体
  • 批准号:
    10724882
  • 财政年份:
    2023
  • 资助金额:
    $ 6.72万
  • 项目类别:
Uncertainty aware virtual treatment planning for peripheral pulmonary artery stenosis
外周肺动脉狭窄的不确定性虚拟治疗计划
  • 批准号:
    10734008
  • 财政年份:
    2023
  • 资助金额:
    $ 6.72万
  • 项目类别:
Enhancing Hypnotic Medication Discontinuation in Primary Care through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
通过监督药物逐渐减量和数字认知行为失眠治疗,加强初级保健中催眠药物的停药
  • 批准号:
    10736443
  • 财政年份:
    2023
  • 资助金额:
    $ 6.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了